Unigene Laboratories, a provider of design, delivery, manufacture and development of peptide-based therapeutics, has entered into a clinical manufacturing agreement with Cara Therapeutics.
Under the agreement, Unigene is expected utilize its peptide manufacturing technology to offer clinical supply material for a Phase 3 study of experimental drug CR845, to be conducted by Cara.
CR845 is a peripherally acting kappa opioid agonist being developed as a treatment for both acute and chronic pain.Unigene president and CEO Ashleigh Palmer said they are pleased to have had early success with Cara via the results of a feasibility study, then to be selected as their partner of choice to manufacture its Phase 1 study clinical trial material, and believe this transaction represents further validation of their oral delivery technology.
